Oryzon Genomics S.A.
BME: ORY.MC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Madrid Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carlos Manuel Buesa Arjol
- Employees
- 47
- Headquarters
- Cornellà de Llobregat, Spain
- IPO year
- 2015
- Market cap
- €215.0M
- Website
- https://www.oryzon.com
Loading ORY…
Loading profile data…Frequently asked questions about ORY
What does Oryzon Genomics S.A. (ORY.MC) do?
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS...
Where does ORY.MC trade?
Oryzon Genomics S.A. (ORY.MC) trades on the Madrid Stock Exchange.
What sector is ORY.MC in?
Oryzon Genomics S.A. (ORY.MC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Oryzon Genomics S.A.?
Carlos Manuel Buesa Arjol is the chief executive officer of Oryzon Genomics S.A. (ORY.MC).
Where is Oryzon Genomics S.A. headquartered?
Oryzon Genomics S.A. is headquartered in Spain.
Does ORY.MC pay a dividend?
Oryzon Genomics S.A. (ORY.MC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ORY.MC go public?
Oryzon Genomics S.A. (ORY.MC) completed its initial public offering in 2015.